These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20007564)

  • 1. Hematopoietic stem-cell transplantation for adults with sickle cell disease.
    Abboud MR
    N Engl J Med; 2009 Dec; 361(24):2380-1. PubMed ID: 20007564
    [No Abstract]   [Full Text] [Related]  

  • 2. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.
    Hsieh MM; Kang EM; Fitzhugh CD; Link MB; Bolan CD; Kurlander R; Childs RW; Rodgers GP; Powell JD; Tisdale JF
    N Engl J Med; 2009 Dec; 361(24):2309-17. PubMed ID: 20007560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation.
    Hill QA; Hill A; Collyns TA; Pearce RM; Cook G
    Bone Marrow Transplant; 2008 Apr; 41(8):749-51. PubMed ID: 18195685
    [No Abstract]   [Full Text] [Related]  

  • 4. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
    Peggs KS; Sureda A; Qian W; Caballero D; Hunter A; Urbano-Ispizua A; Cavet J; Ribera JM; Parker A; Canales M; Mahendra P; Garcia-Conde J; Milligan D; Sanz G; Thomson K; Arranz R; Goldstone AH; Alvarez I; Linch DC; Sierra J; Mackinnon S;
    Br J Haematol; 2007 Oct; 139(1):70-80. PubMed ID: 17854309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell-depleted nonmyeloablative stem cell transplantation: what is the optimum balance between the intensity of host conditioning and the degree of T cell depletion of the graft?
    Chakrabarti S; McDonald D; Milligan DW
    Bone Marrow Transplant; 2001 Aug; 28(3):313-4. PubMed ID: 11536002
    [No Abstract]   [Full Text] [Related]  

  • 6. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML.
    Malladi RK; Peniket AJ; Littlewood TJ; Towlson KE; Pearce R; Yin J; Cavenagh JD; Craddock C; Orchard KH; Olavarria E; McQuaker G; Collin M; Marks DI;
    Bone Marrow Transplant; 2009 May; 43(9):709-15. PubMed ID: 19029965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Non-myeloablative or reduced intensity stem cell transplantation preparative regimens].
    Hino M; Yamane T
    Nihon Rinsho; 2003 Sep; 61(9):1535-41. PubMed ID: 14515720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimerism does not predict for outcome after alemtuzumab based conditioning.
    Michaelis L; Lin S; Joseph L; Artz AS; Kline J; Pollyea D; Stock W; Rich E; Collins-Jones D; Casey B; Del Cerro P; van Besien K
    Bone Marrow Transplant; 2007 Jul; 40(2):181. PubMed ID: 17502895
    [No Abstract]   [Full Text] [Related]  

  • 9. Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease.
    Saraf SL; Oh AL; Patel PR; Jalundhwala Y; Sweiss K; Koshy M; Campbell-Lee S; Gowhari M; Hassan J; Peace D; Quigley JG; Khan I; Molokie RE; Hsu LL; Mahmud N; Levinson DJ; Pickard AS; Garcia JG; Gordeuk VR; Rondelli D
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):441-8. PubMed ID: 26348889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of refractory autoimmune hemolytic anemia with monthly rituximab following nonmyeloablative stem cell transplantation for sickle cell disease.
    Raj A; Bertolone S; Cheerva A
    J Pediatr Hematol Oncol; 2004 May; 26(5):312-4. PubMed ID: 15111785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes.
    Lim ZY; Pearce L; Ho AY; Barber L; Ingram W; Usai M; Tobal K; Devereux S; Pagliuca A; Mufti GJ
    Br J Haematol; 2007 Aug; 138(4):517-26. PubMed ID: 17608767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of stem cell transplantation in the management of chronic lymphocytic leukaemia.
    Tam CS; Khouri I
    Hematol Oncol; 2009 Jun; 27(2):53-60. PubMed ID: 19358149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem cell transplantation for autoimmune diseases.
    Burt RK; Verda L; Statkute L; Quigley K; Yaung K; Brush M; Oyama Y
    Clin Adv Hematol Oncol; 2004 May; 2(5):313-9. PubMed ID: 16163198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.
    Krishnan B; Else M; Tjonnfjord GE; Cazin B; Carney D; Carter J; Ketterer N; Catovsky D; Ethell M; Matutes E; Dearden CE
    Br J Haematol; 2010 Jun; 149(6):907-10. PubMed ID: 20201944
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation.
    Giralt S
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S36-43. PubMed ID: 16720202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of busulfan, cladribine and alemtuzumab as reduced intensity conditioning for stem cell transplantation.
    Halaburda K; Marianska B; Warzocha K; Nasilowska-Adamska B; Szczepinski A; Tomaszewska A; Sawecka J; Skulimowska J
    Ann Transplant; 2009; 14(2):7-12. PubMed ID: 19487787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cell transplantation for multiple myeloma.
    Gasparetto C
    Cancer Control; 2004; 11(2):119-29. PubMed ID: 15024348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemphigus vulgaris treated with allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning.
    Suslova IM; Theodoropoulos DS; Cullen NA; Tetarnikova MK; Tetarnikov AS; Kolchak NA
    Eur Rev Med Pharmacol Sci; 2010 Sep; 14(9):785-8. PubMed ID: 21061838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors.
    Popat U; Carrum G; May R; Lamba R; Krance RA; Heslop HE; Brenner MK
    Bone Marrow Transplant; 2005 Jun; 35(12):1127-32. PubMed ID: 15834432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogenic hematopoietic stem cell transplantation in sickle cell disease.
    Furstenau DK; Tisdale JF
    Transfus Apher Sci; 2021 Feb; 60(1):103057. PubMed ID: 33485798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.